Gil-Ad Irit, Shtaif Biana, Levkovitz Yechiel, Dayag Michal, Zeldich Ella, Weizman Abraham
Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Campus Rabin, Petah-Tiqva 49100, Israel, and Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel.
J Mol Neurosci. 2004;22(3):189-98. doi: 10.1385/JMN:22:3:189.
In this study we aimed to (1). screen phenothiazines for cytotoxic activity in glioma, neuroblastoma, and primary mouse brain tissue; and (2). determine the mechanism of the cytotoxic effect (apoptosis, necrosis) and the roles of calmodulin inhibition and sigma receptor modulation. Rat glioma (C6) and human neuroblastoma (SHSY-5Y) cell lines were treated with different phenothiazines. All agents induced a dose-dependent decrease in viability and proliferation, with the highest activity elicited by thioridazine. Sensitivity to thioridazine of glioma and neuroblastoma cells was significantly higher (p < 0.05) than that of primary mouse brain culture (IC50 11.2 and 15.1 microM vs 41.3 microM, respectively). The N-mustard fluphenazine induced significantly lower cytotoxicity in glioma cells, compared to fluphenazine. The sigma receptor selective ligand (+)-SK&F10047 increased viability slightly while combined with fluphenazine; SK&F10047 did not alter fluphenazine activity. Flow cytometry of propidium iodide (PI)-stained glioma cells treated with thioridazine, fluphenazine, or perphenazine (6-50 microM) resulted in a concentration-dependent increase of fragmented DNA up to 94% vs 3% in controls by all agents. Thioridazine (12.5 microM)-treated glioma cells costained with PI and Hoechst 33342 revealed a red fluorescence of fragmented nuclei in treated cells and a blue fluorescence of intact control nuclei. After 4-h exposure to thioridazine (25 and 50 microM), a 25- to 30-fold increase in caspase-3 activity in neuroblastoma cells was noted. Overall, the marked apoptotic effect of phenothiazines in brain-derived cancer cells, and the low sensitivity of primary brain tissue suggest the potential use of selected agents as therapeutic modalities in brain cancer.
在本研究中,我们旨在:(1)筛选吩噻嗪类药物对胶质瘤、神经母细胞瘤和原代小鼠脑组织的细胞毒性活性;(2)确定细胞毒性作用的机制(凋亡、坏死)以及钙调蛋白抑制和σ受体调节的作用。用不同的吩噻嗪类药物处理大鼠胶质瘤(C6)和人神经母细胞瘤(SHSY-5Y)细胞系。所有药物均诱导细胞活力和增殖呈剂量依赖性下降,其中硫利达嗪的活性最高。胶质瘤和神经母细胞瘤细胞对硫利达嗪的敏感性显著高于原代小鼠脑培养物(IC50分别为11.2和15.1微摩尔/升,而原代小鼠脑培养物为41.3微摩尔/升,p < 0.05)。与氟奋乃静相比,N-芥子气氟奋乃静在胶质瘤细胞中诱导的细胞毒性显著更低。σ受体选择性配体(+)-SK&F10047与氟奋乃静联合使用时可轻微提高细胞活力;SK&F10047不改变氟奋乃静的活性。用硫利达嗪、氟奋乃静或奋乃静(6 - 50微摩尔/升)处理碘化丙啶(PI)染色的胶质瘤细胞,通过流式细胞术检测发现,所有药物均可使断裂DNA浓度依赖性增加,最高可达94%,而对照组为3%。用硫利达嗪(12.5微摩尔/升)处理的胶质瘤细胞与PI和Hoechst 33342共染色,结果显示处理组细胞中细胞核断裂呈现红色荧光,而完整的对照细胞核呈现蓝色荧光。在暴露于硫利达嗪(25和50微摩尔/升)4小时后,神经母细胞瘤细胞中的半胱天冬酶-3活性增加了25至30倍。总体而言,吩噻嗪类药物对脑源性癌细胞具有显著的凋亡作用,而原代脑组织敏感性较低,这表明某些选定药物有可能作为脑癌的治疗方式。